See more : Sitio Royalties Corp. (STRDW) Income Statement Analysis – Financial Results
Complete financial analysis of Solid Biosciences Inc. (SLDB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Solid Biosciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Metallis Resources Inc. (MTLFF) Income Statement Analysis – Financial Results
- HQ Global Education Inc. (HQGE) Income Statement Analysis – Financial Results
- Naturally Splendid Enterprises Ltd. (NSPDF) Income Statement Analysis – Financial Results
- Hamakyorex Co., Ltd. (9037.T) Income Statement Analysis – Financial Results
- Wildsky Resources Inc. (HWTHF) Income Statement Analysis – Financial Results
Solid Biosciences Inc. (SLDB)
About Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 8.09M | 13.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 76.56M | 2.41M | 58.74M | 3.92M | 2.82M | 1.57M | 448.00K | 56.00K | 0.00 |
| Gross Profit | -76.56M | 5.69M | -45.12M | -3.92M | -2.82M | -1.57M | -448.00K | -56.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 70.25% | -331.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 76.56M | 78.42M | 58.74M | 64.88M | 94.74M | 57.97M | 39.91M | 20.12M | 4.19M |
| General & Administrative | 27.75M | 28.95M | 27.14M | 21.58M | 24.58M | 17.72M | 14.95M | 5.46M | 2.37M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.75M | 28.95M | 27.14M | 21.58M | 24.58M | 17.72M | 14.95M | 5.46M | 2.37M |
| Other Expenses | 0.00 | -381.00K | 2.00K | 1.94M | 515.00K | 270.00K | 1.46M | 1.43M | -103.00K |
| Operating Expenses | 104.32M | 107.37M | 85.87M | 86.46M | 119.32M | 75.69M | 54.86M | 25.58M | 6.56M |
| Cost & Expenses | 104.32M | 107.37M | 85.87M | 86.46M | 119.32M | 75.69M | 54.86M | 25.58M | 6.56M |
| Interest Income | 7.14M | 2.62M | 64.00K | 115.00K | 1.58M | 619.00K | 219.00K | 369.00K | 3.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.58M | 2.41M | 2.96M | 3.92M | 2.82M | 1.57M | 448.00K | 56.00K | 6.56M |
| EBITDA | -93.43M | -96.87M | -69.29M | -84.37M | -116.49M | -75.69M | -54.41M | -25.52M | 119.00K |
| EBITDA Ratio | 0.00% | -1,333.38% | -508.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -104.32M | -106.45M | -72.25M | -88.41M | -119.32M | -75.69M | -54.86M | -25.58M | -6.56M |
| Operating Income Ratio | 0.00% | -1,315.20% | -530.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.30M | 20.47M | 66.00K | -1.83M | 2.10M | 889.00K | 1.68M | 1.80M | -100.00K |
| Income Before Tax | -96.02M | -85.98M | -72.19M | -88.29M | -117.22M | -74.80M | -53.18M | -23.77M | -6.66M |
| Income Before Tax Ratio | 0.00% | -1,062.28% | -530.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -20.47M | -64.00K | 1.83M | -1.58M | 889.00K | -1.28M | -2.60M | -287.00K |
| Net Income | -96.02M | -65.51M | -72.12M | -90.12M | -115.64M | -74.80M | -52.12M | -21.54M | -6.38M |
| Net Income Ratio | 0.00% | -809.36% | -529.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.83 | -7.70 | -10.13 | -26.03 | -43.05 | -33.73 | -24.26 | -16.80 | -4.97 |
| EPS Diluted | -4.83 | -7.70 | -10.13 | -26.03 | -43.05 | -33.73 | -24.26 | -16.80 | -4.97 |
| Weighted Avg Shares Out | 19.88M | 8.51M | 7.12M | 3.46M | 2.69M | 2.22M | 2.15M | 1.28M | 1.28M |
| Weighted Avg Shares Out (Dil) | 19.88M | 8.51M | 7.12M | 3.46M | 2.69M | 2.22M | 2.15M | 1.28M | 1.28M |
2 Net Current Asset Value Stocks to Consider
There are some investors who buy U.S.-listed stocks that are trading below their liquidation values because they believe they can gain a lot from these stocks after the market has reappraised the share prices to near or above the liquidation...
Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Co-Founder, President and Chief Executive Officer, and Carl...
Solid Biosciences und Forge Biologics geben eine Vertragsentwicklung für virale Vektoren und eine cGMP-Herstellungspartnerschaft bekannt
CAMBRIDGE, Massachusetts, USA & COLUMBUS, Ohio--(BUSINESS WIRE)--Solid Biosciences Inc. (Solid, Nasdaq: SLDB), ein Life-Science-Unternehmen, das sich auf die Weiterentwicklung sinnvoller Therapien für Duchenne-Muskeldystrophie (Duchenne) konzentriert, und Forge Biologics, ein auf Zell- und Gentherapie fokussiertes Auftragsentwicklungs- und Fertigungsunternehmen (CDMO), gaben eine...
Solid Biosciences et Forge Biologics annoncent un partenariat de développement et fabrication cGMP sous contrat, de vecteur viral
CAMBRIDGE, Massachusetts et Columbus, Ohio--(BUSINESS WIRE)--Solid Biosciences Inc. (Solid, Nasdaq : SLDB), une société du secteur des sciences de la vie, axée sur l’évolution des thérapies significatives pour la dystrophie musculaire de Duchenne (myopathie de Duchenne), et Forge Biologics, une...
Solid Biosciences y Forge Biologics anuncian un contrato de desarrollo de vectores virales y una asociación de fabricación cGMP
CAMBRIDGE, Mass. Y COLUMBUS, Ohio--(BUSINESS WIRE)--Solid Biosciences Inc. (Solid, Nasdaq: SLDB), una empresa de ciencias de la vida centrada en el avance de terapias significativas para la distrofia muscular de Duchenne (Duchenne), y Forge Biologics, una organización de desarrollo y...
Solid Biosciences e Forge Biologics annunciano una partnership finalizzata allo sviluppo per conto terzi di un vettore virale e una produzione conforme alle attuali buone pratiche di fabbricazione
CAMBRIDGE, Massachusetts, e COLUMBUS, Ohio--(BUSINESS WIRE)--Solid Biosciences Inc. (Solid, Nasdaq: SLDB), società operante nel ramo delle scienze naturali specializzata nel perfezionamento di terapie efficaci per la distrofia muscolare di Duchenne (Duchenne), e Forge Biologics, azienda dedita allo sviluppo e alla...
Solid Biosciences en Forge Biologics kondigen Viral Vector Contract Development en cGMP Manufacturing Partnership aan
CAMBRIDGE, Mass. & COLUMBUS, Ohio--(BUSINESS WIRE)--Solid Biosciences Inc. (Solid, Nasdaq: SLDB), een life sciences-bedrijf dat zich richt op het bevorderen van zinvolle therapieën voor spierdystrofie van Duchenne (Duchenne), en Forge Biologics, een cel en gentherapie-gerichte contract development and manufacturing organization...
Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
CAMBRIDGE, Mass. & COLUMBUS, Ohio--(BUSINESS WIRE)--Solid Biosciences Inc. (Solid, Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), and Forge Biologics, a cell and gene therapy-focused contract development and manufacturing organization (CDMO), announced...
Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
CAMBRIDGE, Mass. & COLUMBUS, Ohio--(BUSINESS WIRE)-- #genetherapy--Solid and Forge Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
7 Best Penny Stocks to Buy on the Nasdaq for October
Penny stocks have a place in every portfolio when adjusted for risk. These 7 have the added safety of a Nasdaq listing.
Source: https://incomestatements.info
Category: Stock Reports